Edition:
India

Regeneron Pharmaceuticals Inc (REGN.O)

REGN.O on Nasdaq

295.31USD
23 May 2018
Change (% chg)

$0.63 (+0.21%)
Prev Close
$294.68
Open
$292.29
Day's High
$296.26
Day's Low
$291.10
Volume
567,605
Avg. Vol
978,863
52-wk High
$543.55
52-wk Low
$281.89

Chart for

About

Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have... (more)

Overall

Beta: 1.59
Market Cap(Mil.): $50,356.19
Shares Outstanding(Mil.): 107.15
Dividend: --
Yield (%): --

Financials

UPDATE 3-Regeneron's newer drugs disappoint, shares slip

* Shares down 2 pct (Adds background, comments from conf. call and analyst, updates shares)

03 May 2018

BRIEF-Regeneron Reports Q1 GAAP Earnings Per Share $4.16

* REGENERON REPORTS FIRST QUARTER 2018 FINANCIAL AND OPERATING RESULTS

03 May 2018

Regeneron's first quarter profit soars 92 percent

May 3 Regeneron Pharmaceuticals Inc on Thursday posted a 92 percent rise in quarterly profit, as demand for its flagship eye treatment Eylea and eczema drug Dupixent increased.

03 May 2018

Regeneron/Sanofi cut heart drug price to $4,500-$6,600 for Express Scripts

Regeneron Pharmaceuticals Inc and Sanofi SA will slash the price of their expensive cholesterol drug for Express Scripts Holdings Co customers in exchange for greater patient access, with some savings to be shared with consumers, the companies said on Tuesday.

01 May 2018

BRIEF-Regeneron And Sanofi To Lower Net Price Of Praluent For Express Scripts Patients

* REGENERON AND SANOFI TO LOWER NET PRICE OF PRALUENT® (ALIROCUMAB) INJECTION IN EXCHANGE FOR STRAIGHTFORWARD, MORE AFFORDABLE PATIENT ACCESS FOR EXPRESS SCRIPTS PATIENTS

01 May 2018

Sanofi/Regeneron cut Praluent drug price in Express Scripts deal

May 1 Sanofi and Regeneron Pharmaceuticals said on Tuesday they had agreed to cut the price of their potent cholesterol drug, Praluent, under a deal with Express Scripts, the largest U.S. manager of prescription benefits.

01 May 2018

Regeneron/Sanofi to cut price of heart drug in Express Scripts deal

May 1 Regeneron Pharmaceuticals and Sanofi will cut the net price of their expensive cholesterol drug for Express Scripts customers in exchange for greater patient access, with some savings to be shared with consumers, the companies said on Tuesday.

01 May 2018

BRIEF-Regeneron Says FDA To Conduct Priority Review Of Cemiplimab As A Potential Treatment For Advanced Cutaneous Squamous Cell Carcinoma

* FDA TO CONDUCT PRIORITY REVIEW OF CEMIPLIMAB AS A POTENTIAL TREATMENT FOR ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA

30 Apr 2018

BRIEF-Regeneron Pharma CEO's 2017 Compensation Was $26.5 Million

* REGENERON PHARMACEUTICALS INC SAYS PRESIDENT AND CEO LEONARD S. SCHLEIFER'S 2017 TOTAL COMPENSATION WAS $26.5 MILLION VERSUS $28.3 MILLION IN 2016 – SEC FILING

24 Apr 2018

European Medicines Agency to review Sanofi-Regeneron's Dupixent, Cemiplimab

PARIS The European Medicines Agency (EMA) will review the Dupixent (dupilumab) and Cemiplimab products being developed by drugmakers Sanofi and Regeneron, the companies said on Tuesday.

03 Apr 2018

Competitors

  Price Chg
Novartis AG (NOVN.S) CHF76.16 -0.52
Pfizer Inc. (PFE.N) $35.97 +0.25
Bayer AG (BAYGn.DE) €102.74 -2.30
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €66.23 -0.14
Merck & Co., Inc. (MRK.N) $59.17 +0.72
Amgen, Inc. (AMGN.OQ) $179.94 +1.58
Roche Holding Ltd. (ROG.S) CHF219.25 -4.65
Roche Holding Ltd. (RO.S) CHF223.40 -5.40
Eli Lilly And Co (LLY.N) $82.68 +0.46

Earnings vs. Estimates